US Patent

US8410167 — Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality

Method of Use · Assigned to Sanofi SA · Expires 2029-04-16 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using dronedarone to prevent cardiovascular hospitalization or mortality.

USPTO Abstract

Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.

Drugs covered by this patent

dronedarone-hydrochloride (DRONEDARONE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1387`	—	dronedarone-hydrochloride

Patent Metadata

Patent number: US8410167
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-16
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.